Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.

David Moon J Spencer HauckXue JiangHolly QuangLingfan XuFan ZhangXia GaoRobert WildJeffrey I EverittEverardo MaciasYiping HeJiaoti Huang

Published in: The Prostate (2023)

The prodrug DRP-104 blocks glutamine carbon and nitrogen utilization, thereby inhibiting CRPC growth and inducing apoptosis. Targeting glutamine metabolism pathways with DRP-104 represents a promising therapeutic strategy for CRPC.

Keyphrases

cancer therapy
oxidative stress
endoplasmic reticulum stress
signaling pathway
cell death
drug delivery
cell cycle arrest
cell proliferation
drug release
pi k akt